AMG 176_Combo in multiple hematologic indications_20150161
Research payments
$3,539,142
Through program year 2024, $3,539,142 in research payments was reported against AMG 176_Combo in multiple hematologic indications_20150161, across 143 payments, paid by Amgen Inc..
- Paid by
- Amgen Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $483,265 | 16 |
| 2023 | Research | $449,137 | 10 |
| 2022 | Research | $411,747 | 19 |
| 2021 | Research | $840,839 | 24 |
| 2020 | Research | $350,837 | 25 |
| 2019 | Research | $1,003,316 | 49 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Anthony Stein Duarte, CA Named on 19 payments
- Tapan Kadia Houston, TX Named on 13 payments
- Paul Shami Salt Lake City, UT Named on 13 payments
- Aaron Rosenberg Sacramento, CA Named on 8 payments
- Noopur Raje Boston, MA Named on 8 payments
- David Siegel Hackensack, NJ Named on 7 payments
- Jyotsna Fuloria New Orleans, LA Named on 6 payments
- James McCloskey Hackensack, NJ Named on 5 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.